文献速递胃肠外科

肿瘤部位分层胃癌淋巴结转移风险与预后:多中心及SEER数据库回顾性分析

Tumor location stratifies lymph node metastasis risk and prognosis in gastric cancer: A retrospective analysis of multicenter data and SEER database.
PubMed 文献 · Surgery · 2026-03-20

该回顾性研究纳入本地队列4926例、国内队列623例及公共数据库4243例根治性胃切除胃癌患者,按肿瘤部位(上、中、下)分层分析。发现相同病理淋巴结分期下上三分之一胃癌生存显著差于中、下三分之一,且死亡风险随转移淋巴结数增加而上三分之一加速更明显,据此建立的新分期系统预后区分优于传统病理TNM。

要点

  • 相同病理淋巴结分期下,上三分之一胃癌生存显著差于中、下三分之一。
  • 上三分之一胃癌死亡风险随转移淋巴结数增加加速上升。
  • 结合肿瘤部位与转移淋巴结数的新病理淋巴结分期预后区分优于传统TNM。

核心结论

  • 相同转移淋巴结数下上三分之一胃癌生存显著差于中、下三分之一。
  • 结合肿瘤部位与转移淋巴结数建立的新病理淋巴结分期预后区分优于传统病理TNM分期。

研究设计与样本

  • 回顾性分析根治性胃切除的原发性胃癌患者,本地队列4926例、国内队列623例、公共数据库4243例。
  • 按肿瘤部位分为上、中、下胃三个亚组。
  • 采用限制性立方样条评估转移淋巴结数与死亡率的非线性关系,Cox比例风险模型评估临床因素对预后的影响,单因素分析评估转移淋巴结与肿瘤部位对总生存的影响。

主要发现

  • 相同病理淋巴结分期内,不同肿瘤部位生存存在差异。
  • 上三分之一胃癌在病理淋巴结0-3期(P<.001)及4期(P<.05)生存显著差于中、下三分之一。
  • 中三分之一与下三分之一胃癌生存相似(P>.05)。
  • 无论部位,死亡风险随转移淋巴结数增加而逐渐升高。
  • 上三分之一胃癌死亡风险随转移淋巴结数增加加速上升较中、下组更明显(总体P<.001,非线性P<.001),该趋势在病理T分期中一致。

关键数值与推荐

  • 上三分之一胃癌在病理淋巴结0-3期生存差于中、下三分之一(P<.001)。
  • 上三分之一胃癌在病理淋巴结4期生存差于中、下三分之一(P<.05)。
  • 中三分之一与下三分之一胃癌生存差异无统计学意义(P>.05)。

临床怎么用

  • 病理淋巴结分期时应考虑原发肿瘤部位,上三分之一胃癌可能需更密切的预后评估。
  • 可参考结合肿瘤部位与转移淋巴结数的新分期系统进行预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the significant relationship between the number of metastatic lymph nodes and primary tumor location, which is overlooked in the current pathologic node staging system, this study seeks to optimize pathologic node staging by incorporating this critical factor. METHODS: This study analyzed patients with primary gastric cancer who underwent radical gastrectomy, comprising 4,926 from a local cohort, 623 from a domestic cohort, and 4,243 from a public database. Patients were stratified by tumor location: upper, middle, or lower gastric subgroups. Restricted cubic spline plots evaluated nonlinear relationships between the number of metastatic lymph nodes and mortality across locations. The Cox proportional hazards model was used to assess the effects of clinical factors on patient prognosis. Univariate analyses assessed metastatic lymph nodes and tumor location effects on overall survival. RESULTS: Survival disparities persist by tumor location within identical pathologic node stages. Patients with upper-third gastric cancer show significantly worse survival than middle- or lower-third groups across pathologic node stages (P < .001 for pathologic node 0-3; P < .05 for pathologic node 4), whereas survival for patients with middle versus lower gastric cancer is similar (P > .05). Mortality risk progressively increases with more metastatic lymph nodes regardless of location. Critically, patients in the upper gastric cancer group exhibit a markedly accelerated mortality risk escalation than middle and lower groups (P for overall < .001, P for nonlinear < .001), a trend consistent across pathologic tumor stages. CONCLUSION: This study demonstrated that patients in the upper gastric cancer group have significantly worse survival than those in the middle and lower groups with identical metastatic lymph nodes. Leveraging tumor location and metastatic lymph nodes, we established a novel pathologic node staging system that outperformed the conventional pathologic tumor-node-metastasis staging in prognostic discrimination.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Yang Q, He J, Zhao Q, et al. Tumor location stratifies lymph node metastasis risk and prognosis in gastric cancer: A retrospective analysis of multicenter data and SEER database. Surgery. 2026. PMID: 41861432. doi:10.1016/j.surg.2026.110140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。